TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Single-Blind, Active Control, 18-Week Study to Evaluate the Safety and Efficacy of A New Twice-Daily, Topically Applied LCD Solution vs. Calcipotriol Cream for the Treatment of Adult Subjects With Moderate Plaque Psoriasis
Brief Summary: The purpose of this study is to compare the safety and effectiveness of a new topical LCD solution and a commercially available calcipotriol (Vitamin D) cream in reducing the symptoms of plaque psoriasis and improving the quality of life in adults.


Options:
A: Intervention Type: DRUG; Name: Vehicle (Placebo) applied BID; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: QRX-101 75 mcg/g ointment applied QD; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: QRX-101 75 mcg/g ointment applied BID; Assigned to Arm(s): N/A
B: Arm Label: U0267 Foam; Type: EXPERIMENTAL; Interventions: Drug: U0267 | Arm Label: Vehicle foam; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle | Intervention Type: DRUG; Name: U0267; Assigned to Arm(s): U0267 Foam | Intervention Type: DRUG; Name: Vehicle; Assigned to Arm(s): Vehicle foam
C: Intervention Type: DRUG; Name: Calcipotriol plus betamethasone dipropionate (LEO80185 gel); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: LCD | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: calcipotriol | Intervention Type: DRUG; Name: LCD; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: calcipotriol; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind, Extension Trial of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease
Brief Summary: Gaucher disease, the most prevalent lysosomal storage disorder, is caused by mutations in the human glucocerebrosidase gene (GCD) leading to reduced activity of the lysosomal enzyme glucocerebrosidase and thereby to the accumulation of substrate glucocerebroside (GlcCer) in the cells of the monocyte-macrophage system.

This is an extension trial to Study NCT00376168 and NCT00712348.


Options:
A: Arm Label: Naive 30 Units/kg; Type: EXPERIMENTAL; Interventions: Drug: Taliglucerase alfa | Arm Label: Naive 60 Units/kg; Type: EXPERIMENTAL; Interventions: Drug: Taliglucerase alfa | Arm Label: Switchover; Type: EXPERIMENTAL; Interventions: Drug: Taliglucerase alfa | Intervention Type: DRUG; Name: Taliglucerase alfa; Assigned to Arm(s): Naive 30 Units/kg, Naive 60 Units/kg, Switchover
B: Arm Label: prGCD 30 Units/kg; Type: EXPERIMENTAL; Interventions: Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD) | Arm Label: prGCD 60 Units/kg; Type: EXPERIMENTAL; Interventions: Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD) | Intervention Type: DRUG; Name: Plant cell expressed recombinant glucocerebrosidase (prGCD); Assigned to Arm(s): prGCD 30 Units/kg | Intervention Type: DRUG; Name: Plant cell expressed recombinant glucocerebrosidase (prGCD); Assigned to Arm(s): prGCD 60 Units/kg
C: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Eliglustat tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eliglustat tartrate; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Investigational; Type: EXPERIMENTAL; Interventions: Drug: Eliglustat tartrate | Arm Label: Imiglucerase; Type: ACTIVE_COMPARATOR; Interventions: Drug: Imiglucerase | Intervention Type: DRUG; Name: Eliglustat tartrate; Assigned to Arm(s): Investigational | Intervention Type: DRUG; Name: Imiglucerase; Assigned to Arm(s): Imiglucerase

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IV Study Safety & Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients.
Brief Summary: Eligible patients will undergo this open label initial safety and feasibility study investigating the use of 6 g/day sodium oxybate in mild AD. A total of 5 visits are included with this trial and total subject participation duration of 7-8 weeks. The screening phase will include an initial screening visit and a screening PSG night. After successful screening, subjects will complete a baseline PSG night and undergo a third PSG night to monitor initial safety and compliance with study drug at a dosage of 4.5 g/day of sodium oxybate. Thus the subject will undergo three consecutive nights of PSG in the sleep center. The patient will maintain a dosage of 4.5 g/day for a duration of 7 days leading to Treatment Visit 1. After successful assessment at Treatment Visit 1, the dosage will be increased to 6 g/day for the duration of the trial. At Treatment Visit 2 (day 21), the dosage will be increased to a dosage of 9 g/day, if tolerated by the patient. The remaining visit will occur at 6 weeks after baseline, with Treatment Visit 3 consisting of two consecutive nights of PSG. Participation will be complete after this visit. Phone follow-up will be made at one week post completion visits to assess any wash-out symptoms. Please refer to Figure for flow of the study design.


Options:
A: Arm Label: Gabapentin Enacarbil (GEn); Type: EXPERIMENTAL; Interventions: Drug: Gabapentin Enacarbil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Gabapentin Enacarbil; Assigned to Arm(s): Gabapentin Enacarbil (GEn) | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo
B: Arm Label: Suvorexant; Type: EXPERIMENTAL; Interventions: Drug: Suvorexant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Suvorexant; Assigned to Arm(s): Suvorexant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Zolpidem CR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zolpidem CR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zolpidem CR; Assigned to Arm(s): Zolpidem CR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Sodium Oxybate; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial: Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix (PECEP)
Brief Summary: Placement of a vaginal pessary reduces significantly the rate of spontaneous preterm birth in pregnant women with short cervical length at 18-22 weeks scan.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: Silicon ring (Arabin Pessary) | Intervention Type: DEVICE; Name: Silicon ring (Arabin Pessary); Assigned to Arm(s): 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: 8% progesterone vaginal gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Vaginal Gel | Intervention Type: DRUG; Name: 8% progesterone vaginal gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Vaginal Gel; Assigned to Arm(s): 2
C: Arm Label: Cervical Pessary; Type: EXPERIMENTAL; Interventions: Device: Cervical pessary | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Cervical pessary; Assigned to Arm(s): Cervical Pessary
D: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: indomethacin and antibiotics; Type: EXPERIMENTAL; Interventions: Drug: Indomethacin and antibiotics (cefazolin or clindamycin) | Intervention Type: DRUG; Name: Indomethacin and antibiotics (cefazolin or clindamycin); Assigned to Arm(s): indomethacin and antibiotics

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial: Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix (PECEP)
Brief Summary: Placement of a vaginal pessary reduces significantly the rate of spontaneous preterm birth in pregnant women with short cervical length at 18-22 weeks scan.


Options:
A: Arm Label: Vaginal micronized progesterone; Type: EXPERIMENTAL; Interventions: Drug: Vaginal micronized progesterone | Arm Label: Cervical pessary; Type: ACTIVE_COMPARATOR; Interventions: Device: Cervical pessary | Intervention Type: DRUG; Name: Vaginal micronized progesterone; Assigned to Arm(s): Vaginal micronized progesterone | Intervention Type: DEVICE; Name: Cervical pessary; Assigned to Arm(s): Cervical pessary
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: Silicon ring (Arabin Pessary) | Intervention Type: DEVICE; Name: Silicon ring (Arabin Pessary); Assigned to Arm(s): 2
C: Arm Label: Expectant Management; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Placement of cervical pessary since 23 weeks until 37 weeks; Type: EXPERIMENTAL; Interventions: Device: Device: Silicon ring (Arabin Pessary) | Intervention Type: DEVICE; Name: Device: Silicon ring (Arabin Pessary); Assigned to Arm(s): Placement of cervical pessary since 23 weeks until 37 weeks
D: Arm Label: Pessary; Type: EXPERIMENTAL; Interventions: Device: arabin pessary | Arm Label: No Pessary; Type: ACTIVE_COMPARATOR; Interventions: Device: no pessary | Intervention Type: DEVICE; Name: arabin pessary; Assigned to Arm(s): Pessary | Intervention Type: DEVICE; Name: no pessary; Assigned to Arm(s): No Pessary

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Brief CBT for Anxiety and Advanced Cancer
Brief Summary: RATIONALE: Providing cognitive-behavioral therapy (CBT) may reduce anxiety and improve quality of life of patients with advanced cancer.

PURPOSE: To examine the development and pilot testing of a brief cognitive-behavioral therapy intervention to treat anxiety and improve quality of life in patients with advanced cancer.

Hypothesis: Patients with anxiety associated with advanced cancer who receive CBT will report significantly fewer anxiety symptoms compared to those in the comparison condition.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Meaning Centered Group Psychotherapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Group Psychotherapy | Intervention Type: BEHAVIORAL; Name: Meaning Centered Group Psychotherapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Supportive Group Psychotherapy; Assigned to Arm(s): 2
B: Arm Label: Clinical Improvisation Instrumental Music Therapy; Type: EXPERIMENTAL; Interventions: Other: Clinical Improvisation Instrumental Music Therapy | Arm Label: Clinical Vocal Improvisation; Type: EXPERIMENTAL; Interventions: Other: Clinical Vocal Improvisation | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Clinical Improvisation Instrumental Music Therapy; Assigned to Arm(s): Clinical Improvisation Instrumental Music Therapy | Intervention Type: OTHER; Name: Clinical Vocal Improvisation; Assigned to Arm(s): Clinical Vocal Improvisation
C: Arm Label: Intervention - CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Cognitive Behavioral Therapy | Arm Label: Routine Care Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Brief Cognitive Behavioral Therapy; Assigned to Arm(s): Intervention - CBT
D: Arm Label: e-Psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: e-CBT | Arm Label: Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: e-CBT; Assigned to Arm(s): e-Psychotherapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Glasgow Supported Self-Management Randomised Controlled Trial for Patients With Moderate/ Severe COPD - GSuST
Brief Summary: Training patients to alter their own therapy early in the course of a developing exacerbation (self-management) has been shown to improve outcomes in asthma, but there is no good evidence on this for patients with Chronic Obstructive Pulmonary Disease (COPD). Case management, with patients having an identified contact who helps them access care when necessary, has been shown to improve outcomes in recent studies. A combined approach, called supported selfmanagement, may be particularly suitable for this socially and often educationally disadvantaged group of patients.We propose to identify 500 patients at the time of an exacerbation to test this combined strategy in a randomised manner. The primary outcome measure will be readmission to hospital or death due to COPD, important in terms of patient preferences, quality of life and health costs. This will provide important information about intermediate care for COPD patients which should influence service provision within the NHS in Scotland


Options:
A: Arm Label: Pulmonary daoyin therapy of China; Type: EXPERIMENTAL; Interventions: Other: Pulmonary daoyin therapy of China | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: usual care | Intervention Type: OTHER; Name: Pulmonary daoyin therapy of China; Assigned to Arm(s): Pulmonary daoyin therapy of China | Intervention Type: OTHER; Name: usual care; Assigned to Arm(s): Control
B: Arm Label: 1: i-DSMP; Type: EXPERIMENTAL; Interventions: Behavioral: Internet DSMP | Arm Label: 2: f-DSMP; Type: EXPERIMENTAL; Interventions: Behavioral: Face-to-Face Dyspnea Self-management | Arm Label: 3: AC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control | Intervention Type: BEHAVIORAL; Name: Internet DSMP; Assigned to Arm(s): 1: i-DSMP | Intervention Type: BEHAVIORAL; Name: Face-to-Face Dyspnea Self-management; Assigned to Arm(s): 2: f-DSMP | Intervention Type: BEHAVIORAL; Name: Attention Control; Assigned to Arm(s): 3: AC
C: Arm Label: 1 Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supported self management training and support | Arm Label: 2; Type: NO_INTERVENTION; Interventions: Behavioral: Supported self management training and support | Intervention Type: BEHAVIORAL; Name: Supported self management training and support; Assigned to Arm(s): 1 Intervention group, 2
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Ususal care | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: RT management | Intervention Type: OTHER; Name: RT management; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Ususal care; Assigned to Arm(s): Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Glasgow Supported Self-Management Randomised Controlled Trial for Patients With Moderate/ Severe COPD - GSuST
Brief Summary: Training patients to alter their own therapy early in the course of a developing exacerbation (self-management) has been shown to improve outcomes in asthma, but there is no good evidence on this for patients with Chronic Obstructive Pulmonary Disease (COPD). Case management, with patients having an identified contact who helps them access care when necessary, has been shown to improve outcomes in recent studies. A combined approach, called supported selfmanagement, may be particularly suitable for this socially and often educationally disadvantaged group of patients.We propose to identify 500 patients at the time of an exacerbation to test this combined strategy in a randomised manner. The primary outcome measure will be readmission to hospital or death due to COPD, important in terms of patient preferences, quality of life and health costs. This will provide important information about intermediate care for COPD patients which should influence service provision within the NHS in Scotland


Options:
A: Arm Label: Telemedicine; Type: ACTIVE_COMPARATOR; Interventions: Device: Telemedicine | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedicine
B: Arm Label: Tool + Self-management Support Program; Type: EXPERIMENTAL; Interventions: Device: Tool, Behavioral: Self-management Support Program | Arm Label: Self- management Support Program; Type: EXPERIMENTAL; Interventions: Behavioral: Self-management Support Program | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Tool; Assigned to Arm(s): Tool + Self-management Support Program | Intervention Type: BEHAVIORAL; Name: Self-management Support Program; Assigned to Arm(s): Self- management Support Program, Tool + Self-management Support Program
C: Arm Label: Intervention- Home Pulmonary Rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention- Home-based Pulmonary Rehabilitation | Arm Label: Control- Choice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention- Home-based Pulmonary Rehabilitation; Assigned to Arm(s): Intervention- Home Pulmonary Rehabilitation
D: Arm Label: 1 Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supported self management training and support | Arm Label: 2; Type: NO_INTERVENTION; Interventions: Behavioral: Supported self management training and support | Intervention Type: BEHAVIORAL; Name: Supported self management training and support; Assigned to Arm(s): 1 Intervention group, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Glasgow Supported Self-Management Randomised Controlled Trial for Patients With Moderate/ Severe COPD - GSuST
Brief Summary: Training patients to alter their own therapy early in the course of a developing exacerbation (self-management) has been shown to improve outcomes in asthma, but there is no good evidence on this for patients with Chronic Obstructive Pulmonary Disease (COPD). Case management, with patients having an identified contact who helps them access care when necessary, has been shown to improve outcomes in recent studies. A combined approach, called supported selfmanagement, may be particularly suitable for this socially and often educationally disadvantaged group of patients.We propose to identify 500 patients at the time of an exacerbation to test this combined strategy in a randomised manner. The primary outcome measure will be readmission to hospital or death due to COPD, important in terms of patient preferences, quality of life and health costs. This will provide important information about intermediate care for COPD patients which should influence service provision within the NHS in Scotland


Options:
A: Arm Label: 1 Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supported self management training and support | Arm Label: 2; Type: NO_INTERVENTION; Interventions: Behavioral: Supported self management training and support | Intervention Type: BEHAVIORAL; Name: Supported self management training and support; Assigned to Arm(s): 1 Intervention group, 2
B: Intervention Type: BEHAVIORAL; Name: Intermediate care package; Assigned to Arm(s): N/A
C: Arm Label: Group 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Behavioral: COPD Self-management Education | Intervention Type: BEHAVIORAL; Name: COPD Self-management Education; Assigned to Arm(s): Group 2
D: Arm Label: Intercom; Type: EXPERIMENTAL; Interventions: Other: INTERdisciplinary COMmunity-based COPD management (INTERCOM) | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: INTERdisciplinary COMmunity-based COPD management (INTERCOM); Assigned to Arm(s): Intercom

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Glasgow Supported Self-Management Randomised Controlled Trial for Patients With Moderate/ Severe COPD - GSuST
Brief Summary: Training patients to alter their own therapy early in the course of a developing exacerbation (self-management) has been shown to improve outcomes in asthma, but there is no good evidence on this for patients with Chronic Obstructive Pulmonary Disease (COPD). Case management, with patients having an identified contact who helps them access care when necessary, has been shown to improve outcomes in recent studies. A combined approach, called supported selfmanagement, may be particularly suitable for this socially and often educationally disadvantaged group of patients.We propose to identify 500 patients at the time of an exacerbation to test this combined strategy in a randomised manner. The primary outcome measure will be readmission to hospital or death due to COPD, important in terms of patient preferences, quality of life and health costs. This will provide important information about intermediate care for COPD patients which should influence service provision within the NHS in Scotland


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: case management | Arm Label: 2; Type: OTHER; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: case management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): 2
B: Intervention Type: BEHAVIORAL; Name: Intermediate care package; Assigned to Arm(s): N/A
C: Arm Label: 1 Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2 Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Action plan | Intervention Type: BEHAVIORAL; Name: Action plan; Assigned to Arm(s): 2 Intervention
D: Arm Label: 1 Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supported self management training and support | Arm Label: 2; Type: NO_INTERVENTION; Interventions: Behavioral: Supported self management training and support | Intervention Type: BEHAVIORAL; Name: Supported self management training and support; Assigned to Arm(s): 1 Intervention group, 2

Answer: D